This article is about Gilead's Lenacapavir. This medication is up for use as a PrEP option & treatment for those facing multidrug resistance. It is an HIV capsid inhibitor. Capsid inhibitors affect enzymes & proteins viruses need to replicate. The novel thing about this drug is that it's biannual. A shot given only twice a year has a lot of perks, especially for those who have difficulty with pills.
This sounds amazing. It's a new medication with a newer approach. That's awesome. However, this is also a bit worrisome. What if it fails? It could mean a several months people weren't protected from HIV or treating their virus. 6 months is long time between intervals. Maybe I'm overly concerned. But, this will be the 1st medication of its kind, I think an abundance of concern is warranted.
That's all for now, take care.
Cya...
No comments:
Post a Comment